NCT07727083 Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
| NCT ID | NCT07727083 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rong Tao |
| Condition | Extranodal NK/T-cell Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2026-08-11 |
| Primary Completion | 2035-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2026-08-11 with a primary completion date of 2035-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multicenter, non-interventional, ambidirectional cohort study of Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases. The study consists of a retrospective clinical cohort of 500 consecutively diagnosed patients with extranodal NK/T-cell lymphoma and a prospective clinical-biological cohort of 1,000 newly diagnosed patients with extranodal NK/T-cell lymphoma, aggressive NK-cell leukemia, systemic chronic active Epstein-Barr virus disease of T/NK-cell type, or Epstein-Barr virus-positive nodal T/NK-cell lymphoma. The study will characterize clinical features, treatment pathways, response, relapse or progression patterns, and long-term survival. The prospective cohort will additionally undergo standardized collection of peripheral blood and optional tumor tissue specimens at predefined clinical time points. Clinical, molecular, viral, and immune biomarkers will be evaluated for their associations with treatment response, treatment failure, disease progression, and survival. No treatment is assigned by the study.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older. * Newly diagnosed Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease meeting World Health Organization diagnostic criteria. * For the retrospective cohort: diagnosis of extranodal NK/T-cell lymphoma between January 1, 2017 and December 31, 2025 at a participating center. * For the prospective cohort: diagnosis between June 1, 2026 and December 31, 2030 of one of the following: * Extranodal NK/T-cell lymphoma; * Aggressive NK-cell leukemia; * Systemic chronic active Epstein-Barr virus disease of T/NK-cell type; or Epstein-Barr virus-positive nodal T/NK-cell lymphoma. * Availability of essential diagnostic, staging, and treatment information. * For the prospective cohort: written informed consent and successful collection of the protocol-required baseline peripheral blood specimen. Exclusion Criteria: * For the retrospective cohort: no usable survival follow-up information, inability to confirm survival status, or inability to calculate the principal survival outcomes. * For the prospective cohort: unwillingness or inability to participate in protocol-defined longitudinal clinical follow-up.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07727083 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Extranodal NK/T-cell Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07727083 currently recruiting?
Yes, NCT07727083 is actively recruiting participants. Contact the research team at hkutao@hotmail.com for enrollment information.
Where is the NCT07727083 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07727083 clinical trial?
NCT07727083 is sponsored by Rong Tao. The trial plans to enroll 1,500 participants.